WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.

Employees

12,435

Sector

Biotechnology & Medical Research

Calendar

Mar. 24 - Q4 2024 Earnings Release

More about the company

Quotes

Date	Price	Change	Volume
25-03-21	26.35 $	-4.70%	61,456,000
25-03-20	27.65 $	-2.98%	49,554,190
25-03-19	28.50 $	+1.97%	44,419,730
25-03-18	27.95 $	+5.08%	82,145,750
25-03-17	26.60 $	-0.19%	42,779,130

Delayed Quote Hong Kong S.E., March 21, 2025 at 04:08 am EDT

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

AAA

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

24.58CNY

Average target price

21.08CNY

Spread / Average Target

-14.23%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Hong Kong S.E. Other stock markets 04:08:23 2025-03-21 am EDT			5-day change	1st Jan Change
26.35 ^HKD	-4.70%		-1.13%	+50.06%

Mar. 03	WuXi Biologics Launches EffiX?? Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production	CI
Feb. 24	Hong Kong Stocks Fall Amid US Restrictions on Chinese Investments; WuXi AppTec Stocks Slide 10%	MT

Capitalization	101B 108B 13.89B 12.84B 12.27B 10.76B 19.93B 1,195B 22.15B 141B 53.83B 525B 52.07B 51.02B 2,071B	P/E ratio 2024 *	30.7x	P/E ratio 2025 *	25.5x
Enterprise value	94.57B 101B 13.04B 12.06B 11.52B 10.11B 18.72B 1,122B 20.8B 132B 50.55B 493B 48.9B 47.91B 1,945B	EV / Sales 2024 *	5.26x	EV / Sales 2025 *	4.68x
Free-Float	86.37%	Yield 2024 *	-	Yield 2025 *	-

WuXi Biologics Launches EffiX?? Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production	Mar. 03	CI
Hong Kong Stocks Fall Amid US Restrictions on Chinese Investments; WuXi AppTec Stocks Slide 10%	Feb. 24	MT
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$30.59 From HK$19.30, Keeps at Buy	Feb. 20	MT
China hawk picked for key US Commerce Dept job	Feb. 12	RE
UOB Kay Hian Upgrades Wuxi Biologics to Buy from Sell, Price Target is HK$23	Feb. 04	MT
China Pharma Group WuXi Gains as Trump's TikTok Move Buoys Mood	Jan. 20	DJ
WuXi Biologics Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-15-2025 09:00 AM	Jan. 15
WuXi Biologics Inc. Announces Change of Address of Principal Place of Business in Hong Kong	Jan. 10	CI
WuXi Biologics (Cayman) Subsidiary to Sell Vaccines Manufacturing Facility in Ireland for $500 Million	Jan. 07	MT
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million	Jan. 07	DJ
WuXi Biologics Announces Agreement with Candid Therapeutics, Inc. on Trispecific T-Cell Engager	Jan. 06	CI
Hong Kong Stocks Begin Week in Green; WuXi AppTec, WuXi Biologics Jump 9%	Dec. 09	MT
Senior US House Democrats Oppose Blacklisting of China-Linked Firms from US-Funded Research	Dec. 08	MT

Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$30.59 From HK$19.30, Keeps at Buy	Feb. 20	MT
UOB Kay Hian Upgrades Wuxi Biologics to Buy from Sell, Price Target is HK$23	Feb. 04	MT
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$19.30 From HK$23.25, Keeps at Buy	24-08-22	MT
Nomura Adjusts WuXi Biologics (Cayman)'s Price Target to HK$23.25 From HK$53.65, Keeps at Buy	24-07-24	MT
Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target is HK$14	24-06-27	MT

WuXi Biologics (Cayman) Inc. Stock

Equities

2269

KYG970081173

Biotechnology & Medical Research

Valuation: WuXi Biologics (Cayman) Inc.

Chart: WuXi Biologics (Cayman) Inc.

Latest news: WuXi Biologics (Cayman) Inc.

Last Transcript: WuXi Biologics (Cayman) Inc.

Analysts' recommendations: WuXi Biologics (Cayman) Inc.

Press Releases: WuXi Biologics (Cayman) Inc.

News in other languages: WuXi Biologics (Cayman) Inc.

Quotes and Performance

Course Extremes

Managers and Directors: WuXi Biologics (Cayman) Inc.

ETFs: WuXi Biologics (Cayman) Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

WuXi Biologics Cayman : Launches EffiXTM Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production	Mar. 03	PU
WuXi Biologics Showcase Green CRDMO at 2025 JPM, Which Achieves up to 80% PCF Reduction	Feb. 07	AQ
JPM Highlights \| WuXi Biologics CEO Dr. Chris Chen: Poised for Accelerated Growth	Jan. 16	PU
WuXi Biologics Cayman : to Participate at 43rd Annual J.P. Morgan Healthcare Conference	Jan. 15	PU
WuXi Biologics Cayman : 43rd Annual J.P. Morgan Healthcare Conference Presentation	Jan. 13	PU

La china WuXi Biologics venderá a Merck sus instalaciones de vacunas en Irlanda por 500 millones de dólares	Jan. 06
MÄRKTE ASIEN/Honkgong nimmt wieder Fahrt nach oben auf	24-10-04
MÄRKTE ASIEN/Uneinheitlich - Anleger halten sich vor US-Daten zurück	24-09-10
MÄRKTE ASIEN/Etwas fester - US-Biotech-Gesetz belastet in China	24-09-10
MÄRKTE ASIEN/Yen auf 34-Jahres-Tief stützt Kurse in Tokio	24-03-27

1 day	-4.70%
1 week	-1.13%
Current month	+17.37%
1 month	+1.35%
3 months	+54.82%
6 months	+96.94%
Current year	+50.06%

Manager	Title	Age	Since
Zhi Sheng Chen CEO	Chief Executive Officer	53	2015-12-31
Ming Tu DFI	Director of Finance/CFO	55	2021-08-22
Ji Jie Gu CTO	Chief Tech/Sci/R&D Officer	58	-

Director	Title	Age	Since
Ge Li CHM	Chairman	57	2014-01-31
Zhi Sheng Chen BRD	Director/Board Member	53	2014-01-31
Wei Chang Zhou BRD	Director/Board Member	60	2016-04-30

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
WUXI BIOLOGICS (CAYMAN) INC.	-4.70%	-1.13%	+102.07%	-54.84%	13.89B
VERTEX PHARMACEUTICALS INCORPORATED	-1.37%	-0.31%	+21.06%	+99.78%	129B
REGENERON PHARMACEUTICALS, INC.	-0.62%	-1.26%	-31.92%	-4.93%	70.47B
ARGENX SE	+0.11%	+3.23%	+53.69%	+100.71%	37.52B
BEIGENE, LTD.	-4.04%	-2.78%	+65.75%	+35.23%	27.1B
WUXI APPTEC CO., LTD.	-3.72%	+4.80%	+39.80%	-34.92%	26.52B
BIONTECH SE	-0.88%	-4.11%	+3.87%	-45.38%	22.89B
SUMMIT THERAPEUTICS INC.	+1.59%	-5.00%	+486.05%	+472.46%	14.57B
INSMED INCORPORATED	+1.46%	+4.40%	+202.38%	+239.94%	14.47B
GENMAB A/S	-0.58%	-3.57%	-34.51%	-43.68%	12.56B
Average	-1.28%	-0.59%	+90.82%	+76.44%	36.92B
Weighted average by Cap.	-1.28%	-0.34%	+44.43%	+65.97%

	2024 *	2025 *
Net sales	17.99B 19.29B 2.48B 2.29B 2.19B 1.92B 3.56B 213B 3.96B 25.14B 9.62B 93.77B 9.3B 9.12B 370B	20.25B 21.71B 2.79B 2.58B 2.47B 2.16B 4.01B 240B 4.45B 28.29B 10.82B 106B 10.47B 10.26B 416B
Net income	3.33B 3.57B 459M 425M 406M 356M 659M 39.52B 733M 4.65B 1.78B 17.36B 1.72B 1.69B 68.51B	4.04B 4.33B 557M 515M 492M 431M 799M 47.88B 888M 5.64B 2.16B 21.03B 2.09B 2.04B 82.99B
Net Debt	-6.13B -6.57B -846M -782M -747M -655M -1.21B -72.74B -1.35B -8.57B -3.28B -31.95B -3.17B -3.11B -126B	-6.05B -6.49B -835M -772M -738M -647M -1.2B -71.82B -1.33B -8.46B -3.24B -31.55B -3.13B -3.07B -124B